fluorodeoxyglucose f18 has been researched along with wzb117 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Ahn, JM; Chen, M; Choe, JH; Choi, H; Endo, H; Goodwin, J; Helke, KL; Inoue, M; Jenkins, DMR; Jeong, JY; Kim, JW; Lee, SY; Minna, JD; Neugent, ML; Robinson, MW; Ruthenborg, RJ; Shackelford, DB; Singh, PK; Takeda, N; Wake, M; Xuan, Z; Yoo, H | 1 |
1 other study(ies) available for fluorodeoxyglucose f18 and wzb117
| Article | Year |
|---|---|
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cohort Studies; Deoxyglucose; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Hydroxybenzoates; Lung; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Phenotype; Positron-Emission Tomography; Prognosis; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |